AllSight
Companies · SLS · Pharmaceutical Preparations

SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group, Inc. (SLS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

SELLAS Life Sciences Group, Inc. (SLS) stock — financials & valuation

Key numbers for SELLAS Life Sciences Group, Inc. (SLS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 43/100 — a percentile rank of SELLAS Life Sciences Group, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$2.3B
EV / EBITDA-61.0×
Return on equity-23.6%
ROIC5126.5%
Debt / equity0.0×
Dividend yield0.0%

Is SELLAS Life Sciences Group, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from SELLAS Life Sciences Group, Inc.’s own financial statements and shown as context, never as advice.

Aug 11, 2026
Quarter met EPS expectations as trials advanced, but dilution rose sharply
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact